[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2001232340A1 - Novel isoxazole and thiazole compounds and use thereof as drugs - Google Patents

Novel isoxazole and thiazole compounds and use thereof as drugs

Info

Publication number
AU2001232340A1
AU2001232340A1 AU2001232340A AU3234001A AU2001232340A1 AU 2001232340 A1 AU2001232340 A1 AU 2001232340A1 AU 2001232340 A AU2001232340 A AU 2001232340A AU 3234001 A AU3234001 A AU 3234001A AU 2001232340 A1 AU2001232340 A1 AU 2001232340A1
Authority
AU
Australia
Prior art keywords
group
thiazole compounds
atom
drugs
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001232340A
Inventor
Rika Nagao
Hideo Ohta
Akihiro Ueno
Tomoko Watanabe
Mikio Yagi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kirin Brewery Co Ltd
Original Assignee
Kirin Brewery Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery Co Ltd filed Critical Kirin Brewery Co Ltd
Publication of AU2001232340A1 publication Critical patent/AU2001232340A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to novel isoxazole and thiazole compounds having an excellent lysophosphatidic acid (LPA) receptor antagonistic activity represented by general formula Ä1Ü or salts thereof: <IMAGE> wherein R1 and R2 represents an optionally substituted alkyl group or the like; R3 represents a hydrogen atom or the like; R4 represent a group selected from the group consisting of (I) optionally substituted phenyl, aryl, or heterocycle, (II) substituted or nonsubstituted alkyl, and (III) substituted or nonsubstituted alkenyl, alternatively, R3 and R4 may form a ring structure together with a carbon atom to which they bind; and X represents an oxygen atom or a sulfur atom, provided that, when R3 is a hydrogen atom, R4 represents a group other than methyl, and the use thereof as a medicine.
AU2001232340A 2000-02-18 2001-02-19 Novel isoxazole and thiazole compounds and use thereof as drugs Abandoned AU2001232340A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-41922 2000-02-18
JP2000041922 2000-02-18
PCT/JP2001/001173 WO2001060819A1 (en) 2000-02-18 2001-02-19 Novel isoxazole and thiazole compounds and use thereof as drugs

Publications (1)

Publication Number Publication Date
AU2001232340A1 true AU2001232340A1 (en) 2001-08-27

Family

ID=18565067

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001232340A Abandoned AU2001232340A1 (en) 2000-02-18 2001-02-19 Novel isoxazole and thiazole compounds and use thereof as drugs

Country Status (11)

Country Link
US (1) US6964975B2 (en)
EP (1) EP1258484B1 (en)
AT (1) ATE420878T1 (en)
AU (1) AU2001232340A1 (en)
CY (1) CY1110263T1 (en)
DE (1) DE60137405D1 (en)
DK (1) DK1258484T3 (en)
ES (1) ES2320320T3 (en)
PT (1) PT1258484E (en)
TW (1) TWI288136B (en)
WO (1) WO2001060819A1 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
ATE446303T1 (en) 2001-01-30 2009-11-15 Univ Virginia AGONISTS AND ANTAGONISTS OF SPHINGOSINE-1 PHOSPHATE RECEPTORS
JP4396808B2 (en) 2001-02-08 2010-01-13 小野薬品工業株式会社 Urological disease therapeutic agent comprising LPA receptor modulator
JPWO2003007991A1 (en) * 2001-07-17 2004-11-04 小野薬品工業株式会社 Pancreatic secretion regulator comprising LPA receptor modulator
WO2003099765A1 (en) * 2002-05-28 2003-12-04 Ono Pharmaceutical Co., Ltd. β-ALANINE DERIVATIVE AND USE THEREOF
JPWO2004002530A1 (en) 2002-06-26 2005-10-27 小野薬品工業株式会社 Chronic disease treatment
US7361368B2 (en) * 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
EP1546110A4 (en) 2002-07-30 2008-03-26 Univ Virginia Compounds active in sphingosine 1-phosphate signaling
TW200408393A (en) 2002-10-03 2004-06-01 Ono Pharmaceutical Co Antagonist of lysophosphatidine acid receptor
US8821473B2 (en) 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8383158B2 (en) 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US7524638B1 (en) 2003-06-27 2009-04-28 Osi Pharmaceuticals, Inc. Methods for identification of modulators of OSGPR114 or OSGPR78 activity, and their use in the treatment of disease
JP4692281B2 (en) * 2003-08-05 2011-06-01 味の素株式会社 New azole compounds
WO2005041899A2 (en) 2003-11-03 2005-05-12 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
BRPI0607435A2 (en) 2005-02-14 2010-04-06 Univ Virginia compound or a pharmaceutically acceptable salt or ester thereof, and, use of a compound
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US8828433B2 (en) * 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
FR2889190A1 (en) 2005-08-01 2007-02-02 Merck Sante Soc Par Actions Si New imidazole carboxamides, useful to treat e.g. pathologies associated with the insulin resistance syndrome, are fructose-1,6-biphosphatase inhibitors
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP1986623A2 (en) 2006-01-27 2008-11-05 University Of Virginia Patent Foundation Method for treatment of neuropathic pain
EP1987013A1 (en) 2006-02-09 2008-11-05 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US8741326B2 (en) 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
WO2008064320A2 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
JP2010510249A (en) 2006-11-21 2010-04-02 ユニバーシティ オブ バージニア パテント ファンデーション Sphingosine = 1-tetralin analog having 1-phosphate agonist activity
JP2010510251A (en) 2006-11-21 2010-04-02 ユニバーシティ オブ バージニア パテント ファンデーション Benzocycloheptyl analog having sphingosine = 1-phosphate receptor activity
DE102007047738A1 (en) * 2007-10-05 2009-04-09 Merck Patent Gmbh imidazole derivatives
KR101649482B1 (en) 2008-05-05 2016-08-19 사노피 Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
TWI450898B (en) * 2008-07-04 2014-09-01 Sigma Tau Res Switzerland Sa Aryl isoxazole compounds with antitumoural activities
WO2010068775A2 (en) * 2008-12-11 2010-06-17 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
US8722014B2 (en) * 2009-05-01 2014-05-13 Washington University 1 H-[1, 2, 3] triazole substituted amino acids and uses thereof
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
IN2012DN00754A (en) * 2009-08-04 2015-06-19 Amira Pharmaceuticals Inc
PT2481725E (en) 2009-09-25 2015-05-21 Astellas Pharma Inc Substituted amide compound
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) * 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
AR079022A1 (en) 2009-11-02 2011-12-21 Sanofi Aventis DERIVATIVES OF CYCLIC CARBOXYL ACID SUBSTITUTED WITH ACILAMINE, ITS USE AS PHARMACEUTICAL PRODUCTS, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD
WO2011159632A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye
WO2011159635A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions
JP5944823B2 (en) * 2010-07-02 2016-07-05 あすか製薬株式会社 Heterocyclic compound and p27Kip1 degradation inhibitor
MX347544B (en) * 2010-12-07 2017-05-02 Bristol Myers Squibb Co Polycyclic lpa1 antagonist and uses thereof.
CN103443098B (en) * 2011-01-30 2016-03-16 广州源生医药科技有限公司 As the compound of the antagonist of lpa receptor, composition and application thereof
EP2694496A1 (en) * 2011-04-05 2014-02-12 Amira Pharmaceuticals, Inc. 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders
US20150164874A1 (en) * 2011-05-25 2015-06-18 Intermune, Inc. Pirfenidone and anti-fibrotic therapy in selected patients
BR112014003499A2 (en) 2011-08-15 2017-06-13 Intermune Inc pharmaceutically acceptable compounds or salts thereof and pharmaceutical compositions and their uses of effective amounts and methods for treating, preventing, reversing, stopping or retarding the progression of selected disease or condition of fibrosis, cancer or respiratory disorders and modulating receptor activity in cells
WO2013070879A1 (en) 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
CN103987858A (en) 2011-11-22 2014-08-13 英特芒尼公司 Methods of diagnosing and treating idiopathic pulmonary fibrosis
EP2850062B1 (en) * 2012-05-18 2017-07-19 Sanofi Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
CA2896701C (en) * 2012-12-28 2020-10-06 Ube Industries, Ltd. Halogen-substituted heterocyclic compound
EA033923B1 (en) * 2013-03-15 2019-12-10 Эпиджен Байосайенсиз, Инк. Heterocyclic compounds useful in the treatment of diseases
EA038294B1 (en) * 2013-05-24 2021-08-05 Эпиджен Байосайенсиз, Инк. Heterocyclic compounds useful in the treatment of diseases
CN104788343A (en) * 2014-01-16 2015-07-22 同济大学 Ortho-substituted allyl carbamate compound and preparation method thereof
KR102433588B1 (en) * 2014-06-27 2022-08-19 우베 가부시키가이샤 Salt of halogen-substituted heterocyclic compound
WO2016197009A1 (en) 2015-06-05 2016-12-08 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
CN112074515A (en) 2017-12-19 2020-12-11 百时美施贵宝公司 Cyclohexyl acid isoxazoles as LPA antagonists
JP7526096B2 (en) 2017-12-19 2024-07-31 ブリストル－マイヤーズ スクイブ カンパニー Cyclohexyl isoxazole azines as LPA antagonists
PL3710438T3 (en) 2017-12-19 2022-01-31 Bristol-Myers Squibb Company Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
WO2019126084A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
US11447475B2 (en) 2017-12-19 2022-09-20 Bristol-Myers Squibb Company Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
CA3104465A1 (en) * 2018-06-18 2019-12-26 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013075A1 (en) 1993-11-12 1995-05-18 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
US5861359A (en) * 1995-07-25 1999-01-19 Fmc Corporation Herbicidal phenylmethoxphenyl heterocycles
WO1998027213A1 (en) 1996-12-18 1998-06-25 Medical Research Council Lysophosphatidic acid acyltransferase gene and its use
SE9904044D0 (en) * 1999-11-09 1999-11-09 Astra Ab Compounds
GB0003256D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use

Also Published As

Publication number Publication date
US20030114505A1 (en) 2003-06-19
PT1258484E (en) 2009-04-03
ES2320320T3 (en) 2009-05-21
TWI288136B (en) 2007-10-11
EP1258484A1 (en) 2002-11-20
EP1258484B1 (en) 2009-01-14
DE60137405D1 (en) 2009-03-05
ATE420878T1 (en) 2009-01-15
DK1258484T3 (en) 2009-04-20
CY1110263T1 (en) 2015-01-14
US6964975B2 (en) 2005-11-15
EP1258484A4 (en) 2003-04-23
WO2001060819A1 (en) 2001-08-23

Similar Documents

Publication Publication Date Title
AU2001232340A1 (en) Novel isoxazole and thiazole compounds and use thereof as drugs
IL147651A0 (en) Isoxazoline derivative and herbicide containing the same as the active ingredient
BRPI0213243B8 (en) aromatic heterocyclic compound containing an oxazole, thiazole or imidazole ring, or a pharmaceutically acceptable salt thereof, and pharmaceutical composition
FI943561A (en) New compositions of matter
EP1310494A4 (en) PPAR (delta) ACTIVATORS
GB9910577D0 (en) Chemical compounds
PH12015501098A1 (en) Antituberculous composition comprising oxazole compounds
ES2005186A6 (en) Pyrazolecarbonylamine derivatives and agricultural and horticultural fungicides containing said compounds
EP1357124A4 (en) Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient
BR9508676A (en) Carbamolicarboxamide composition processes to prepare compounds and the composition and to control harmful fungi and use compost and compositions
ES2174077T3 (en) ANTI-CHEMICAL HYDROXYLAMINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS.
SE8101703L (en) NEW ISOXAZOLD DERIVATIVES JUST SET FOR THEIR PREPARATION